Regenxbio (RGNX) Assets Average (2015 - 2025)

Regenxbio's Assets Average history runs 11 years deep, the most recent figure standing at $489.1 million for Q4 2025.

• On a quarterly basis, Assets Average fell 0.7% year-over-year to $489.1 million in Q4 2025; TTM through Dec 2025 was $489.1 million, a 0.7% decrease from a year earlier, with the FY2025 full-year figure at $459.5 million, down 11.63% from the prior year.
• Assets Average eased to $489.1 million in Q4 2025 per RGNX's latest filing, from $553.1 million in the prior quarter.
• Across five years, Assets Average topped out at $1.1 billion in Q1 2022 and bottomed at $478.5 million in Q1 2025.
• The 5-year median for Assets Average is $686.6 million (2023), against an average of $716.3 million.
• Across the five-year window, Assets Average soared 87.8% in 2021 and fell 29.66% in 2023, its largest moves.
• Year by year, Assets Average stood at $957.1 million in 2021, then slipped by 10.3% to $858.5 million in 2022, then decreased by 29.66% to $603.9 million in 2023, then dropped by 18.44% to $492.6 million in 2024, then decreased by 0.7% to $489.1 million in 2025.
• Per Business Quant, the three latest RGNX Assets Average figures stand at $489.1 million (Q4 2025), $553.1 million (Q3 2025), and $536.0 million (Q2 2025).